161973-10-0

• 常用中文名：耐信(埃索美拉唑镁)
• 常用英文名：Esomeprazole
• CAS号：161973-10-0
• 分子式：C₃₄H₃₆MgN₆O₆S₂
• 分子量：713.121
• 相关类别： 原料药 消化系统用药 抗酸及胃黏膜保护药
• 发布时间：2018-06-13 11:29:15
• 更新时间：2026-07-02 11:22:28
• Esomeprazole magnesium 是一种 H+, K+-ATPase 抑制剂,能够有效用于上肠道疾病的研究。

名称

• 中文名: 埃索美拉唑镁
• 英文名: esomeprazole magnesium
• 中文别名: 埃索美拉唑镁原料; 埃索美拉唑镁/钠; 埃索美拉唑镁,10 MM DMSO 溶液; 抑制剂Esomrazole Magnesium(Random Configuration); Esomrazole magnesium :埃索美拉唑镁; 5-甲氧基-2-[(4-甲氧基-3,5-二甲基吡啶-2-基)甲基亚磺酰基]苯并咪唑-1-基镁; 埃索美拉唑杂质; 埃索美拉唑镁原料药; 艾司奥美拉唑镁(三水化合物); 艾美拉唑镁; 埃索美拉唑镁无水合物; (T-4)-双[6-甲氧基-2-[(S)-[(4-甲氧基-3,5-二甲基-2-吡啶基)甲基]亚磺酰基-ΚO]-1H-苯并咪唑-ΚN3]镁; 5-甲氧基-2-{[(4-甲氧基-3,5-二甲基-2-吡啶)甲基]亚磺酰基} -1H-苯并咪唑镁; 埃索美拉唑镁(二水/三水) Esomrazole magnesium
• 英文别名: Magnesium 5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-1-ide; Nexium; (S)-5-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole, magnesium salt (2:1); NEXIUM(esomrazolemagnesium); EsMeprazole Magne-siuM Trihydrate; sulfonium, hydroxy(6-methoxy-1H-benzimidazol-2-yl)[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-, inner salt, magnesium salt (2:1); (-)-Omrazole Magnesium; H 199/18; Esomrazole magnesium Esomrazole magnesium(API); Esomrazole Magnesium, 10 mM in DMSO; Magnesium bis(5-methoxy-2-{(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl}benzimidazol-1-ide); Esomeprazole magnesium; Esomrazole magnesium API; ESOMRAZOLE MAGNESIUM/SODIUM; Magnesium Bis[6-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]benzimidazol-1-ide]; Magnesium bis(5-methoxy-2-{(S)-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}benzimidazol-1-ide); Bis(5-methoxy-2-{(S)-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}benzimidazol-1-ide) magnesium; Esomrazole Magnesium(Random Configuration); (-)-Omeprazole magnesium; H-199/18; omeprazole magnesium; Esomrazole magnesium; Esomrazole magnesium (S-Omrazole magnesium); magnesium 5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methanesulfinyl]-1H-1,3-benzodiazol-1-ide 6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methanesulfinyl]-1H-1,3-benzodiazol-1-ide; Esomrazole magnesium //BP; EsoMrazole MagnesiuM(NexiuM); Solvate of potassium 5-methoxy-2-{(S)-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}benzimidazol-1-ide with ethanol(1:2); Esomrazole magneslum; S-Form magnesium salt; Chebi; 5-Methoxy-2-((S)-((4-Methoxy-3,5-diMethyl-2-pyridyl)Methyl)sulfinyl-1H-benziMidazole MagnesiuM salt; (T-4-(S),(S))-Bis(5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazolato)magnesium; ESOMRAZOLE MAGNESIUM , NON-STERILE, BULK DRUG SUBSTANCE; Esomrazole magnesium 5-Methoxy-2-[(S)-(4-methoxy-3,5-dimethyl-2-pyridinylmethyl)sulfinyl]-1H-benzimidazole magnesium salt; (S)-Omeprazole magnesium; Esomrazole magnesiumQ: What is Esomrazole magnesium Q: What is the CAS Number of Esomrazole magnesium Q: What is the storage condition of Esomrazole magnesium Q: What e the applications of Esomrazole magnesium; MagnesiuM,bis[6-Methoxy-2-[(S)-[(4-Methoxy-3,5-diMethyl-2-pyridinyl)Methyl]sulfinyl-kO]-1H-benziMidazolato-kN3]-, (T-4); (T-4)-Bis(5-methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl-kO)-1H-benzimidazolato-kN1)magnesium; EsMrazole Magne-siuM Trihydrate; 1H-Benzimidazole, 5-methoxy-2-[(S)-[(1S)-(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-, magnesium salt (2:1); Magnesium bis{(6-methoxybenzimidazol-1-id-2-yl)[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfoniumolate}; ESOMRAZOLE MAGNESIUM SAMPLE; (T-4)-bis[6-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl-κO]-1H-benzimidazolato-κN3]-magnesium

物化性质

• 沸点: 600ºC at 760 mmHg
• 分子式: C₃₄H₃₆MgN₆O₆S₂
• 分子量: 713.121
• 闪点: 316.7ºC
• 精确质量: 712.198792
• PSA: 186.82000
• LogP: 6.78900
• 外观性状: 粉末
• 蒸汽压: 2.35E-14mmHg at 25°C
• 储存条件: -20℃

生物活性

• 描述: Esomeprazole magnesium 是一种 H+, K+-ATPase 抑制剂,能够有效用于上肠道疾病的研究。
• 相关类别:
  信号通路 >> 跨膜转运 >> 质子泵
  研究领域 >> 其他
• 靶点:

  H+, K+-ATPase[1]

• 体外研究: 埃索美拉唑镁是H +,K + -ATPase的抑制剂[1]。
• 体内研究: 埃索美拉唑镁(0.5,5,50 mg/kg /天,po)产生增加的胃总抗氧化能力,降低胃脂质过氧化物水平,显着增加超氧化物歧化酶水平,但对小鼠结肠脂质过氧化物水平没有明显影响[1] 。
• 动物实验: 小鼠[1]在这10天的补充实验中，小鼠（n = 10 /组）接受以下内容：1）作为对照组，通过胃灌胃每天口服给予埃索美拉唑（PEG-400）溶解的载体; 2）通过洗胃每日一次口服相当体积的PEG-400中的埃索美拉唑0.5mg / kg; 3）通过洗胃每日一次口服体积相当体积的PEG-400中的埃索美拉唑5mg / kg; 4）埃索美拉唑50 mg / kg，相当体积的PEG-400，每天口服一次，通过洗胃[1]。
• 参考文献:

  [1]. Koch TR, et al. Effect of the H, K-ATPase inhibitor, esomeprazole magnesium, on gut total antioxidant capacity in mice. J Nutr Biochem. 2004 Sep;15(9):522-6.